Stock PV3B EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Market Closed - Deutsche Boerse AG
Other stock markets
 06:59:01 31/05/2024 pm IST 		5-day change 1st Jan Change
9.69 EUR -3.34% Intraday chart for EyePoint Pharmaceuticals, Inc. -4.06% -54.29%
08/05 Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating MT
08/05 Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
EYEPOINT PHARMACEUTICALS, INC. Stock EyePoint Pharmaceuticals, Inc.
-54.29% 56Cr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 74TCr
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 60TCr
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 35TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 32TCr
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 28TCr
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 24TCr
B+
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 21TCr
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 16TCr
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 16TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. PV3B Stock
  5. Ratings EyePoint Pharmaceuticals, Inc.